Cryosa, Inc. is a clinical-stage company focused on developing innovative treatments for moderate to severe Obstructive Sleep Apnea (OSA). The company operates in the medical technology sector and targets patients suffering from OSA, a condition characterized by repeated interruptions in breathing during sleep. Cryosa's proprietary technology offers a minimally invasive, incisionless solution that leverages a controlled cooling process to reduce tissue and open airways, eliminating the need for masks, hoses, or implants. The business model revolves around clinical trials, regulatory approvals, and eventual commercialization of their treatment. Revenue generation is anticipated through the sale of their medical devices and associated therapies once they receive market approval. Cryosa has successfully raised $8.25 million in Series A-2 funding to further develop their breakthrough treatment. The company is currently enrolling participants in a U.S. pilot study, ARCTIC 3, to evaluate the safety and effectiveness of their therapy.

Keywords: Obstructive Sleep Apnea, minimally invasive, incisionless, controlled cooling, clinical-stage, medical technology, OSA treatment, pilot study, Series A funding, airway management.